Mastering TMS: The MagVenture Accelerator Training Path for Canadian Clinicians
With rTMS showing remission rates of 30-35% in patients with medically refractory depression, the difference between clinical success and stalled…
Expanding Neuromodulation: Clinical Training Guide
With the Canadian neuromodulation market projected to reach C$296.8 million by 2030, the shift toward non-invasive therapies like rTMS is no longer a…